These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32927853)

  • 41. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.
    Motwani MP; Colas RA; George MJ; Flint JD; Dalli J; Richard-Loendt A; De Maeyer RP; Serhan CN; Gilroy DW
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution.
    Fredman G; Serhan CN
    Biochem J; 2011 Jul; 437(2):185-97. PubMed ID: 21711247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation.
    Hsiao HM; Sapinoro RE; Thatcher TH; Croasdell A; Levy EP; Fulton RA; Olsen KC; Pollock SJ; Serhan CN; Phipps RP; Sime PJ
    PLoS One; 2013; 8(3):e58258. PubMed ID: 23484005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators.
    Serhan CN
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():44-8. PubMed ID: 19630766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases.
    Giudetti AM; Cagnazzo R
    Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):57-67. PubMed ID: 23064030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specialized Pro-Resolving Mediators and the Lymphatic System.
    Kraft JD; Blomgran R; Lundgaard I; Quiding-Järbrink M; Bromberg JS; Börgeson E
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases.
    Videla LA; Valenzuela R; Del Campo A; Zúñiga-Hernández J
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease.
    Pascoal LB; Palma BB; Chaim FHM; de Castro MM; Damázio TA; Franceschini APMF; Milanski M; Velloso LA; Leal RF
    World J Exp Med; 2022 Jan; 12(1):1-15. PubMed ID: 35096550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Use of Specialized Pro-Resolving Mediators in Biomaterial-Based Immunomodulation.
    Sousa AB; Barbosa JN
    J Funct Biomater; 2023 Apr; 14(4):. PubMed ID: 37103313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The novel lipid mediator PD1
    Hansen TV; Dalli J; Serhan CN
    Prostaglandins Other Lipid Mediat; 2017 Nov; 133():103-110. PubMed ID: 28602942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.
    Serhan CN; Levy BD
    J Clin Invest; 2018 Jul; 128(7):2657-2669. PubMed ID: 29757195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Specialized Pro-Resolving Mediators in Neuropathic Pain.
    Leuti A; Fava M; Pellegrini N; Maccarrone M
    Front Pharmacol; 2021; 12():717993. PubMed ID: 34456731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders.
    Han YH; Lee K; Saha A; Han J; Choi H; Noh M; Lee YH; Lee MO
    Biomol Ther (Seoul); 2021 Sep; 29(5):455-464. PubMed ID: 34162770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs).
    Regidor PA; de la Rosa X; Müller A; Mayr M; Gonzalez Santos F; Gracia Banzo R; Rizo JM
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and Changes in Lipid Mediator Profiling after Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects.
    Irún P; Carrera-Lasfuentes P; Sánchez-Luengo M; Belio Ú; Domper-Arnal MJ; Higuera GA; Hawkins M; de la Rosa X; Lanas A
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pro-resolving and anti-inflammatory effects of resolvins and protectins in rheumatoid arthritis.
    Zhang X; Zhang H
    Inflammopharmacology; 2023 Dec; 31(6):2995-3004. PubMed ID: 37831392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators.
    Norling LV; Ly L; Dalli J
    Curr Opin Clin Nutr Metab Care; 2017 Mar; 20(2):145-152. PubMed ID: 28002074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue.
    Colas RA; Shinohara M; Dalli J; Chiang N; Serhan CN
    Am J Physiol Cell Physiol; 2014 Jul; 307(1):C39-54. PubMed ID: 24696140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases.
    López-Vicario C; Rius B; Alcaraz-Quiles J; García-Alonso V; Lopategi A; Titos E; Clària J
    Eur J Pharmacol; 2016 Aug; 785():133-143. PubMed ID: 25987424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.
    Babar MU; Nassar AF; Nie X; Zhang T; He J; Yeung J; Norris P; Ogura H; Muldoon A; Chen L; Libreros S
    Metabolites; 2024 May; 14(6):. PubMed ID: 38921449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.